Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: Results from an observational database

Circulation: Cardiovascular Quality and Outcomes

Volumn 5, Issue 1, 2012, Pages 52-61

  Pinto, Duane S ^a   Ogbonnaya, Augustina ^b   Sherman, Steven A ^b   Tung, Patricia ^a   Normand, Sharon Lise T ^c,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Analytica International   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bivalirudin; Comparative effectiveness; Economic analysis; Primary percutaneous coronary intervention; ST segment myocardial infarction

Indexed keywords

GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; HIRULOG;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIAC PATIENT; CAUSE OF DEATH; CLINICAL PRACTICE; ECONOMIC ASPECT; FEMALE; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY; ANTITHROMBINS; CORONARY VESSELS; COST-BENEFIT ANALYSIS; ELECTROCARDIOGRAPHY; FEMALE; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860830170     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.111.961938     Document Type: Article

References (26)

1. Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, White K, Goldberg RJ. Predictors of major bleeding in acute coronary syndromes: The Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24:1815-1823. (Pubitemid 37280247)
2. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht H-J, Hoekstra J, Mehran R, Ohman EM, the AI. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-2216. (Pubitemid 44791162)
3. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863. (Pubitemid 37430344)
4. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R, the HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230. (Pubitemid 351724451)
5. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): Final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377:2193-2204.
6. Rassen JA, Mittleman MA, Glynn RJ, Brookhart MA, Schneeweiss S. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J. 2010 Mar; 31(5):561-572.
7. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-Artery bypass grafting and risk of death. N Engl J Med. 2008; 358:771-783. (Pubitemid 351284455)
8. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 2005;353:349-361. (Pubitemid 41132339)
9. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipidlowering therapy and in-hospital mortality following major noncardiac surgery. JAMA. 2004;291:2092-2099. (Pubitemid 38580152)
10. Shwartz M, Young DW, Siegrist R. The ratio of costs to charges: How good a basis for estimating costs? Inquiry. 1995;32:476-481.
11. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 1977: Hillsdale, NJ; Lawrence Erlbaum Associates.
12. Coca-Perraillon M. Local and Global Optimal Propensity Score Matching. In: Proceedings of the SAS Global Forum 2007: Cary, NC; SAS Institute Inc: 186.
13. Gu XS, Rosenbaum PR. Comparison of multivariate matching methods: Structures, distances, and algorithms. Journal of Computational and Graphical Statistics. 1993;2:405-420.
14. Rosenbaum PR. Observational Studies. New York: Springer-Verlag; 2002.
15. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149-1159.
16. Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip DE, Bates ER, Frederick PD, Miller DP, Carrozza JP Jr, Antman EM, Cannon CP, Gibson CM. Hospital delays in reperfusion for ST-elevation myocardial infarction: Implications when selecting a reperfusion strategy. Circulation. 2006;114:2019-2025. (Pubitemid 44706877)
17. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KAA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774-782. (Pubitemid 44268228)
18. Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: Assessment from the acute catheterization and urgent intervention triage strategy trial. Circulation. 2010;121:43-51.
19. Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Stone GW. Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: Analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. J Am Coll Cardiol: Cardiovascular Interventions. 2009;2:624-632.
20. Morrow DA. Antithrombotic therapy to support primary PCI. N Engl J Med. 2008;358:2280-2282. (Pubitemid 351724461)
21. Spencer FA, Moscucci M, Granger CB, Gore JM, Goldberg RJ, Steg PG, Goodman SG, Budaj A, FitzGerald G, Fox KAA, for the GRACE Investigators. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation. 2007; 116:2793-2801. (Pubitemid 350291221)
22. Pinto DS, Stone GW, Shi C, Dunn ES, Reynolds MR, York M, Walczak J, Berezin R, Mehran R, Mclaurin BT, Cox D, Ohman EM, Lincoff AM, Cohen DJ. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol. 2008;52:1758-1768.
23. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ, Abciximab tC, Device Investigation to Lower Late Angioplasty Complications Investigators. Comparison of angioplasty with stenting, with or without Abciximab, in acute myocardial infarction. N Engl J Med. 2002; 346:957-966. (Pubitemid 34983245)
24. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc J-M, Morice M-C, Maillard L, Pansieri M, Choussat R, Pinton P, the ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903. (Pubitemid 32553358)
25. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, Khattab AA, Schultz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schomig A, Investigators I-RT. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359:688-696.
26. Amin AP, Marso SP, Rao SV, Messenger J, Chan PS, House J, Kennedy K, Robertus K, Cohen DJ, Mahoney EM. Cost-effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding. Circ Cardiovasc Qual Outcomes. 2010;3:335-336.